Quantum BioPharma Gains FDA Clearance to Launch Phase 2 Trial for Multiple Sclerosis Drug Lucid-MS

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) — via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM). To hear the NetworkNewsAudio version, visit To read the original editorial, visit: Even large, well-funded competitors are still searching for something better. Several […]

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM).

Quantum BioPharma Gains FDA Clearance to Launch Phase 2 Trial for Multiple Sclerosis Drug Lucid-MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Lucid-MS, allowing the company to proceed directly into a Phase 2 clinical trial for multiple sclerosis. The clearance marks a significant step for the micro-cap biotech, as most drug candidates never reach this stage. The news was highlighted in a NetworkNewsAudio press release titled “A Micro-Cap B…